Torreal retains Rothschild to sell 60% in Alcaliber, Sanofi Aventis joins the sale with its 40%
Torreal habría contratado a Rothschild para vender el 60% en Alcaliber y Sanofi Aventis se sumaría a la venta con su 40%
Intel ID : 254566
|
||||
| Intel ID | 254566 | |||
| Value | ND | |||
| Native Currency | Euro (EUR) | |||
|
Financial Data - Torreal
(31 Dec 2022) |
Revenue: EUR 42,32m EBITDA: EUR 31,95m Net Debt: EUR 0,00m |
|||
| Date |
 |
|||
| Country |  |
|||
| Region | ||||
| Continent | |
|||
| Geography | |
|||
| Subsector (Old TTR Sectors) |
|
|||
| Type |
|
|||
| Intel Grade |
|
|||
| Source |
|
|||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Seller
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Seller
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Financial Advisory
| Parties | Advisor | Notes from Advisors | |||||
|---|---|---|---|---|---|---|---|
|
|
- |
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.